Moderna Celebrates Cancer Breakthrough – Stock Soars by 131%

After the stunning development of its mRNA vaccine against COVID-19, Moderna has now achieved another major success—and the stock market rewarded it immediately. When the company announced yesterday the compelling results of its Phase 3 study on the personalized cancer vaccine mRNA-4157/V940, the stock not only skyrocketed but also dragged an entire industry—and a few short sellers—into the abyss.
A milestone that gives hope
Moderna is no stranger to us: its coronavirus vaccine has saved millions of lives and catapulted the company into the top tier of biotech firms. But now, the company is taking the next big leap—and it could be even more significant. The personalized cancer vaccine, combined with Merck’s established immunotherapy Keytruda, was tested on patients with early-stage melanoma. The results are impressive: the risk of relapse or death was reduced by 44%, and the formation of metastases even dropped by 49%.
This is more than just a number—it’s a sign that this technology has the potential to revolutionize cancer treatment. As Stefano Toppo, Moderna’s Chief Medical Officer, puts it: "For the first time in a large study, we have proven that an mRNA-based vaccine can be more effective than standard therapy."
The market celebrates—and short sellers curse
The market reaction was fierce. Moderna’s stock surged from around $140 to over $300—a gain of more than 100% in a single day! But that wasn’t all: short sellers who had bet against the stock lost $4.8 billion in the blink of an eye. One of the largest "short covering" waves in years, according to Ihor Dusaniwsky of S3 Partners.
I still remember the early reports about Moderna’s COVID-19 vaccine—how many at the time scof



fed and said mRNA technology was still too new and risky. Today, it’s one of the world’s most successful vaccine technologies. And now, the same could be true for cancer treatment.
Not just for Moderna—the entire industry benefits
The news didn’t just send Moderna’s stock soaring. BioNTech, co-developer of the first mRNA COVID-19 vaccine, also saw its stock rise as investors now hope for further applications of mRNA technology. This shows: when a breakthrough like this succeeds, the entire industry benefits.
What’s next?
Moderna plans to submit the data to regulators and aims for approval by 2025. If successful, the vaccine could be used not only for melanomas but also for other cancers like lung, bladder, or kidney cancer.
But as with any such breakthrough, there are critical voices. Dr. Christoph Huber, an oncologist at the University of Mainz, warns: "mRNA therapies are promising, but they are also complex and expensive to produce. We need to see how the long-term results develop."
Conclusion: A Game-Changer—but Not a Guarantee
With this breakthrough, Moderna has proven that mRNA can work not only against viruses but also against cancer. The stock rally shows just how much potential this technology holds—but we should also remember that biotech investments remain high-risk.
For investors, that means caution is warranted. The current hype is understandable, but anyone jumping in now should be aware of the long-term challenges. Still, one thing is certain: this breakthrough will reignite the discussion about mRNA-based therapies—and possibly herald the next major revolution in medicine. The question is just: when?
And who knows—maybe Moderna will soon be in the spotlight again.